MXPA05003551A - Composiciones y metodos para el tratamiento de prostata y otros canceres. - Google Patents

Composiciones y metodos para el tratamiento de prostata y otros canceres.

Info

Publication number
MXPA05003551A
MXPA05003551A MXPA05003551A MXPA05003551A MXPA05003551A MX PA05003551 A MXPA05003551 A MX PA05003551A MX PA05003551 A MXPA05003551 A MX PA05003551A MX PA05003551 A MXPA05003551 A MX PA05003551A MX PA05003551 A MXPA05003551 A MX PA05003551A
Authority
MX
Mexico
Prior art keywords
hsp
dosage unit
unit form
cancers
mrna
Prior art date
Application number
MXPA05003551A
Other languages
English (en)
Inventor
Beraldi Eliana
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of MXPA05003551A publication Critical patent/MXPA05003551A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion hace uso de agentes terapeuticos, los cuales se dirigen a la proteina de choque termico (hsp) 27 in vivo para proporcionar tratamiento a individuos, particularmente individuos humanos, que padecen de cancer de prostata y otros canceres que sobreexpresan la hsp 27. de acuerdo con la invencion, un agente terapeutico, por ejemplo un inhibidor nucleotido ARN y u oligonucleotido antisentido con especificidad de secuencia para mARN de hsp 27, por ejemplo mARN de hsp27 de humano, se administra a un individuo que padece de cancer de prostata o algun otro cancer que expresa niveles elevados de hsp 27, en una cantidad terapeutica eficaz. El agente terapeutico se formula convenientemente en una composicion farmaceutica la cual incluye un vehiculo farmaceuticamente aceptable, y se envasan en la formula de unidad de dosis. Una forma de unidad de dosis preferida es una forma de unidad de dosis inyectable.
MXPA05003551A 2002-10-02 2003-10-02 Composiciones y metodos para el tratamiento de prostata y otros canceres. MXPA05003551A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41585902P 2002-10-02 2002-10-02
US46395203P 2003-04-18 2003-04-18
PCT/CA2003/001588 WO2004030660A2 (en) 2002-10-02 2003-10-02 Compositions for treatment of prostate and other cancers

Publications (1)

Publication Number Publication Date
MXPA05003551A true MXPA05003551A (es) 2005-10-19

Family

ID=32073392

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05003551A MXPA05003551A (es) 2002-10-02 2003-10-02 Composiciones y metodos para el tratamiento de prostata y otros canceres.

Country Status (17)

Country Link
US (8) US7101991B2 (es)
EP (2) EP1545561B1 (es)
JP (2) JP5127138B2 (es)
KR (1) KR101142080B1 (es)
CN (1) CN1703229B (es)
AT (1) ATE465743T1 (es)
AU (1) AU2003278028B2 (es)
CA (1) CA2498026C (es)
DE (1) DE60332363D1 (es)
DK (1) DK1545561T3 (es)
ES (1) ES2345330T3 (es)
IL (1) IL167621A (es)
MX (1) MXPA05003551A (es)
NO (2) NO338310B1 (es)
NZ (1) NZ538841A (es)
WO (1) WO2004030660A2 (es)
ZA (1) ZA200502603B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345330T3 (es) 2002-10-02 2010-09-21 The University Of British Columbia Oligonucleotidos para el tratamiento del cancer de prostata y otros canceres.
US8691780B2 (en) * 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
US20090264502A1 (en) * 2005-08-25 2009-10-22 Bennett C Frank Compositions and their uses directed to hsp27
AU2007215275B2 (en) * 2006-02-10 2013-01-17 The Regents Of The University Of California Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS
US8242258B2 (en) * 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
WO2008106781A1 (en) * 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy
CA2680600A1 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
CA2656577A1 (en) * 2008-04-14 2009-10-14 The University Of British Columbia Method for evaluation of a cancer
AU2009265194A1 (en) * 2008-07-02 2010-01-07 Enzon Pharmaceuticals Inc RNA antagonists targeting Hsp27
CN102099041B (zh) * 2008-07-18 2013-07-31 Ogx科技公司 反义制剂
WO2011054811A1 (en) * 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
KR101217866B1 (ko) * 2010-08-18 2013-01-03 한국원자력의학원 혈관신생 억제용 약학 조성물 및 혈관신생 억제용 활성물질을 스크리닝하는 방법
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
JP5658696B2 (ja) * 2011-02-25 2015-01-28 株式会社ファンケル 皮膚のストレス蓄積度の評価方法
CA2747509C (en) 2011-05-12 2017-07-18 Oncogenex Technologies Inc. Treatment of pulmonary and pleural fibrosis using hsp27 inhibitors
AU2013216361B2 (en) * 2012-02-02 2017-09-07 The University Of British Columbia Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates
GB201204785D0 (en) 2012-03-19 2012-05-02 Queen Mary & Westfield College Method for determining prognosis of prostate cancer in a subject
KR101374585B1 (ko) * 2012-05-02 2014-03-17 연세대학교 산학협력단 ＨＳＰ２７ 발현을 억제하는 ｓｈＲＮＡ
JP2015529073A (ja) 2012-08-20 2015-10-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物可逆性基を有するポリヌクレオチド
EP3174541A1 (de) 2014-07-28 2017-06-07 Technische Universität Dresden Thymin- und chinazolin-dion-derivate zur hemmung von hsp27
AU2016363683B2 (en) * 2015-11-30 2023-04-27 The University Of British Columbia Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840708A (en) * 1992-12-14 1998-11-24 Allegheny University Of The Health Sciences Administration of oligonucleotides antisense to dopamine receptor MRNA for diagnosis and treatment of Neurological pathologies
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
JPH09176011A (ja) * 1995-12-27 1997-07-08 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のフラボノイド含有合成抑制剤
US20060008448A1 (en) * 1996-06-11 2006-01-12 Minzhen Xu Inhibition of li expression in mammalian cells
JPH107559A (ja) 1996-06-18 1998-01-13 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のベルベリン誘導体含有合成抑制剤
US5962262A (en) 1997-07-25 1999-10-05 Incyte Pharmaceuticals, Inc. Human heat shock 27 like protein
US6703228B1 (en) 1998-09-25 2004-03-09 Massachusetts Institute Of Technology Methods and products related to genotyping and DNA analysis
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
IL146565A0 (en) 1999-07-19 2002-07-25 Univ British Columbia A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5
AU2001249317A1 (en) 2000-03-21 2001-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP1523323B1 (en) * 2001-08-23 2013-07-24 Arizona Board Of Regents Reagents and methods for smooth muscle therapies
ES2345330T3 (es) * 2002-10-02 2010-09-21 The University Of British Columbia Oligonucleotidos para el tratamiento del cancer de prostata y otros canceres.
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20090264502A1 (en) * 2005-08-25 2009-10-22 Bennett C Frank Compositions and their uses directed to hsp27
WO2008106781A1 (en) 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy

Also Published As

Publication number Publication date
US9580712B2 (en) 2017-02-28
EP1545561B1 (en) 2010-04-28
DE60332363D1 (de) 2010-06-10
US7847091B2 (en) 2010-12-07
US9404109B2 (en) 2016-08-02
WO2004030660A2 (en) 2004-04-15
EP1545561A2 (en) 2005-06-29
US7550580B2 (en) 2009-06-23
CN1703229B (zh) 2011-01-05
US8772470B1 (en) 2014-07-08
US20060276424A1 (en) 2006-12-07
NO20160655A1 (no) 2016-04-20
WO2004030660A3 (en) 2004-06-10
CA2498026A1 (en) 2004-04-15
NO20052055L (no) 2005-06-23
ES2345330T3 (es) 2010-09-21
ZA200502603B (en) 2006-06-28
US7723312B2 (en) 2010-05-25
US20090221678A1 (en) 2009-09-03
EP2216029A2 (en) 2010-08-11
IL167621A (en) 2011-11-30
DK1545561T3 (da) 2010-08-02
ATE465743T1 (de) 2010-05-15
JP5237996B2 (ja) 2013-07-17
NZ538841A (en) 2006-10-27
US20150232843A1 (en) 2015-08-20
JP2010215669A (ja) 2010-09-30
US20060040886A1 (en) 2006-02-23
US20160326527A1 (en) 2016-11-10
KR101142080B1 (ko) 2012-05-03
EP2216029A3 (en) 2010-12-22
US20140315978A1 (en) 2014-10-23
US20040127441A1 (en) 2004-07-01
JP5127138B2 (ja) 2013-01-23
US9085769B2 (en) 2015-07-21
CN1703229A (zh) 2005-11-30
CA2498026C (en) 2015-06-30
NO338310B1 (no) 2016-08-08
AU2003278028B2 (en) 2008-12-18
JP2006503904A (ja) 2006-02-02
KR20050050111A (ko) 2005-05-27
AU2003278028A1 (en) 2004-04-23
US7101991B2 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
NO20160655A1 (no) Sammensetninger og fremgangsmåter for behandling av prostata- og andre cancere
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
SG148169A1 (en) Combination drug therapy to treat obesity
WO2000049937A3 (en) Trpm-2 antisense therapy
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
WO2003070283A3 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
HK1091127A1 (en) Compounds and methods for downregulating the effects of tgf-beta
Spartalis et al. Histone deacetylase inhibitors and anaplastic thyroid carcinoma
EE200200463A (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks või ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
JP2006503904A5 (es)
MXPA02011247A (es) Quimioterapia de combinacion.
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
JP2004537500A5 (es)
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
MXPA02009984A (es) Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis.
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
EA200501456A1 (ru) Торий- 227 для применения в радиотерапии заболевания мягких тканей
Yu et al. Telomerase activity and telomerase reverse transcriptase expression induced by selenium in rat hepatocytes
GB9930075D0 (en) Medicaments
EP1501948A4 (en) DNA ENZYME FOR INHIBITING PLASMINOGENACTIVATOR INHIBITOR-1

Legal Events

Date Code Title Description
FG Grant or registration